ArticleScientific reports2025
Clinical application value of erythroferrone (ERFE) and hepcidin in pregnant women with thalassemia and iron-deficiency anemia: a comprehensive study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To explore the metabolic levels of ERFE (Erythroferrone) and Hepcidin in pregnant women with thalassemia combined with iron deficiency anemia (IDA), and to analyze the differences in serum ERFE, Hepcidin levels and iron-related indicators before and after iron supplementation in these pregnant women, providing a theoretical basis and effective monitoring indicators for the clinical iron supplementation treatment of pregnant women with thalassemia combined with IDA. The experimental groups comprised:50 thalassemia-monotherapy cases (THAL group), 54 thalassemia with iron-deficiency anemia cases (THAL-IDA group),50 iron-deficiency anemia cases (IDA group).All cases were diagnosed between April 2023 and September 2024, with 50 healthy pregnant women from the same period serving as controls (NC group).All pregnant women had serum and plasma samples collected to measure indicators such as Erythroferrone (ERFE), Hepcidin, complete blood count, and ferritin. The differences in these indicators among the groups were analyzed.For patients in the IDA Group and the THAL-IDA Group, after 4 weeks of iron supplementation using a standardized protocol, blood samples were re-collected to measure the aforementioned indicators and compare the changes before and after iron therapy. (1) General Characteristics, Erythrocyte Parameters, and SF Analysis Across Experimental and Control Groups. Hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) in all experimental groups were significantly lower than those in the NC group, while ERFE levels were significantly higher (P < 0.05). Serum ferritin (SF) and Hepcidin levels were significantly elevated in the NC and THAL groups compared to other groups (P < 0.05), though no significant difference existed between the NC and THAL groups (P > 0.05). Within experimental groups, the THAL group exhibited the highest Hepcidin and SF levels, while the IDA group showed the lowest (P < 0.05). ERFE levels in thalassemia groups (THAL and THAL-IDA) were significantly higher than in non-thalassemia groups (NC and IDA) (P < 0.05). The --
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.